Citius Pharmaceuticals, Inc. (OTCMKTS:CTXR) Files An 8-K Other EventsItem 8.01. Other Material Information.
On November 7, 2017, Citius Pharmaceuticals, Inc. issued a press release entitled “International Study at MD Anderson Sister Institutions Supports Mino-LokTM ”Phase 2b Results Poster Presented at ID Week”. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits
Citius Pharmaceuticals, Inc. ExhibitEX-99.1 2 f8k110717ex99-1_citiuspharma.htm PRESS RELEASE Exhibit 99.1 International Study at MD Anderson Sister Institutions Supports Mino Lok™ Phase 2b Results: Poster Presented at ID Week Results showed a 95% efficacy in salvaging infected catheters for Mino-Lok ™ CRANFORD,…To view the full exhibit click
About Citius Pharmaceuticals, Inc. (OTCMKTS:CTXR)
Citius Pharmaceuticals, Inc., formerly Trail One, Inc., is a pharmaceutical company engaged in developing and commercializing therapeutic products. The Company focuses on developing formulations to manage the delivery and compliance of approved drugs. The Company offers Suprenza, an orally disintegrating tablet and an obesity drug that can be administered with water or dissolved on tongue. The Company also focuses on development of its product candidate, Hydrocortisone-Lidocaine Cream, which is in Phase II study. Its Hydrocortisone-Lidocaine Cream is used to provide anti-inflammatory and anesthetic relief to persons suffering from grade I and II hemorrhoids. Citius Pharmaceuticals, LLC is its subsidiary. The Company has not generated any revenues.